Change of the conference dates: June 15-17, 2020  -  September 17-19, 2024.

The 9th International Conference on Emerging Technologies in Drug Discovery and Development (IAPC-9) will be organized by the International Association of Physical Chemists, ADMET and DMPK Journal and co-organized by Shanghai Hengrui Pharmaceutical Co., Ltd. The conference is aimed at providing a unique global forum where scientists working in different but closely related areas of pharmaceutical research, from drug discovery through to drug development, will meet in a relaxed atmosphere to discuss and rationalize their results and challenges.

    Co-organized by:   

IAPC logo4

Hengrui bez


Read more....

Scientific program
Social events
Abstract submission
SCI journal publication
Other publishing options
Registration options
How to register
Key dates

Featured speakers

Klara Valko
Klara obtained her PhD at Semmerlweis University in Budapest. Since 1995 Klara has been working with the Physico-chemical Characterization Group at GSK. Now she is director of Bio-Mimetic Chromatography Consultancy providing data analysis, biomimetic HPLC method set up and measurements, in vivo drug distribution modelling and various courses to pharmaceutical companies and manufacturers of analytical equipment. Klara is also a honorary professor at University College London, where she has been teaching the Physchem/ADME module for the Drug Discovery. She has published over 100 papers that achieved over 3000 citations. She wrote a book on “Physicochemical and Biomimetic Properties in Drug Discovery; Chromatographic Techniques for lead optimization” published by Wiley in 2014.

Klara ValkoBiomimetic chromatography

Duanyun Si
Dr. Duanyun Si joined Tianjin Institute of Pharmaceutical Research (Tianjin, China) in 2005. as a PI and professor for new drug/formulation ADME assessment to support the drug/formulation development process across China and beyond. In 2009, He became Executive Director in State Key Laboratory of Drug Delivery Technology and Pharmacokinetics. Starting from Oct. 2018, Dr. Si acts as the President in the Professional Committee of Studying Xenobiotics, Chinese Pharmacological Society. Dr. Si's research interests are focused on drug metabolism, drug disposition, bioanalysis, and organic mass spectrometry to support new drug/formulation and generic drug ADME/BE assessments during R&D phases of IND, NDA and ANDA.

Duanyun SiDirector of State Key Laboratory, Tianjin

Johan Gabrielsson
Professor of integrative pharmacology +20 years of industrial experience as Senior Principal Scientist in research areas such as CV & GI & CNS & Cancer & Biologics. Author of the textbooks 'Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications' 5th ed. (2016) and 'Quantitative Pharmacology: An Introduction to Integrative Pharmacokinetic-Phar­macodynamic Analysis' 1st ed. (2012).

Johan GabrielssonProf. of integrative pharmacology

Sylvia Zhao
Dr. Sylvia Zhao is currently the Executive Director, China/Japan Site Head of Pharmacokinetics Sciences (PK Sciences) for the Novartis Institutes of Biomedical Research (NIBR), Shanghai, China. Sylvia received her Ph.D. degree in Pharmaceutical Sciences from University of Toronto. After graduation, she joined the DMPK Department of Hoffmann-La Roche NJ, heading the Lab of Drug-Drug Interaction being responsible for preclinical DMPK support. In 2009 Sylvia became the Head of DMPK in Asia Pacific at Janssen Pharmaceuticals, responsible for DMPK support to China R&D programs and global PK studies of small molecules and biopharmaceuticals in China. In 2013, Sylvia joined CNIBR, leading Clinical Pharmacology in Translational Clinical Oncology, and was then appointed China/Japan Site Head of PK Sciences.

Sylvia ZhaoPrincipal scientist, Roche, Shanghai

Alex Avdeef
Alex Avdeef, PhD, is an AAPS Fellow, and the author of Absorption and Drug Development, Wiley, 2012. For over 40 years, he has been teaching, researching, & developing methods, instruments, & analysis software for measurement of ionization constants, solubility of practically-insoluble drugs, miniaturized dissolution, & permeability. His accomplishments in the development of instrumentation include several well-known instruments currently manufactured by leading companies in the instrument market (e.g., ORION960 Autochemistry System). He has over 120 technical publications in primary scientific journals & chapters in books, 6 patents. He founded in-ADME Research (USA) and co-founded pION INC (USA) in 1996 & Sirius Analytical (UK) in 1989.

Alex AvdeefCEO, in-ADME Research

Yutai Li
Dr. Yutai Li is a Principal Scientist from Merck, USA. Yutai Li obtained her Ph.D. from North Carolina State University. She worked at DuPont, Schering Plough, and University of North Carolina before she joined the investigative toxicology group at safety assessment in Merck & Co. in 2004. She currently works on toxicity biomarker discovery using LC-MS based metabolomics approach. Also, she has been working on mechanisms of drug induced liver injury due to transporter inhibition and oxidative stress using rodent models. She was invited to deliver oral presentations at 2017 ASMS Asilomar metabolomic meeting, 2019 SOLVO meet experter transporter workshop. She had over 20 publications. Representing Merck safety assessment, Yutai is a member of Predictive Safety Testing Consortium (PSTC).

Yutai LiPrincipal scientist, Merck, USA

Christel Bergström
Dr Bergström is Associate Professor in Pharmaceutics at Uppsala University where she is heading a research group focusing on delivery of poorly soluble compounds. She is in the steering committee of the Swedish Drug Delivery Forum where she also leads the Oral Drug Delivery Platform with drug delivery to the colon and intestinal absorption of biologics being in focus. Dr Bergström is the cofounder of Center of Pharmaceutical Informatics at Uppsala University (now UDOPP) She is a cofounder of the Nordic Pharma Network and an EXCO member of a recently awarded NordForsk grant for a Nordic University Hub within patient-oriented products. She is also an EXCO member of the Globalization Pharmaceutics Education Network. In 2017, she was elected Deputy Dean of collaboration (Medicine and Pharmacy) at Uppsala University.

Christel BergströmUppsala University

Weikang Tao
Dr. Weikang Tao has served as corp vice president of Jiangsu Hengrui Medicine Co., Ltd. and the CEO of R&D Centers since Feb. 2014. In this position, he has led the R&D Centers consisting of about 500 scientists and located in China and in the US to discover and develop innovative medicines, ranging from small molecule drugs, therapeutic antibodies and peptides, antibody-drug conjugates and cellular therapies in multiple therapeutic areas.Dr. Tao has published more than 40 peer-reviewed research papers in premier life science journals and he is the holder of many issued and pending patents in drug discovery. He obtained a Ph.D. degree in Molecular & Cell Biology from the University of Medicine & Dentistry of New Jersey in the US. He was a post-doctoral fellow in Prof. Arnold Levine’s Lab at Princeton University.

Weikang TaoCEO, Hengrui R&D

Annete Bauer-Brandl
Annette Bauer-Brandl is an accredited pharmacist with a doctoral degree in Pharmaceutics. Currently she is a Professor in Pharmaceutical Technology at University of Southern Denmark. She is a specialist in the fields of materials science and processing (Quality by Design). She is well known for her awarded Handbook on Formulation, Manufacturing and Quality Assurance of Solid Dosage Forms. She serves at the EDQM and the Danish Pharmacopoeia Committee. Currently her research interest focusses on prediction of oral bioavailability of drugs from formulations, especially of enabling formulations of poorly soluble drugs. Her group has invented a novel biomimetic membrane that allows permeation experiments under harsh conditions such as digestive processes. She published more than 300 scientific contributions.

Annete Bauer-BrandlUniversity of Southern Denmark

Godefridus J. Peters
Godefridus (Frits) J. Peters was appointed 1989 as head of the division of (Biochemical) Pharmacology, and was head of the Laboratory Medical Oncology from 2003-2017. He was appointed as associate-professor in 1992 and as full professor in 2003. The research of Prof. Peters is focused on translation of preclinical pharmacology of anticancer agents to the clinic. Prof Peters was involved in several Phase I and 2 studies of drugs now registered for treatment of cancer such as gemcitabine, pemetrexed, erlotinib, while “failed” clinical studies led to the development of successful drugs. Prof. Peters has authored/co-authored >450 refereed research papers and reviews.

Godefridus J. PetersVMuc Amsterdam, The Netherlands

Fan Wu
Dr. Fan Wu is Senior Principal Scientist at Bristol-Myers Squibb (BMS). As a project manager and modeling lead, he has specific interests in applying quantitative pharmacology modeling strategies to facilitate translational and clinical drug development. Formerly, he was Senior Principal Scientist at Celgene (acquired by BMS in 2019) and Senior Investigator at Novartis, and before that Senior Research Scientist at CFD Research Corporation. Dr. Wu received his PhD degree in Chemical Engineering at the University of New Hampshire and postdoctoral training in Systems Physiology from Professor Daniel Beard’s lab at the Medical College of Wisconsin. He has published 29 peer-reviewed research papers in leading scientific journals.

Fan WuBristol-Myers Squibb

Rolf Hilfiker
Rolf Hilfiker is Head of the Department Solid-State Development at Solvias AG. Rolf obtained his Ph.D in physical chemistry at the University of Basel, Switzerland. From 1987-89 he was Post Doc at SUNY, New York and from 1989-1992 Senior Research Fellow at the University of Basel. He has more than twenty years of experience in an industrial R&D environment at Ciba-Geigy, Novartis, and Solvias. Under his guidance, Solvias became one of the leading solid-state service providers in the world. He is author of more than 60 scientific publications as well as numerous patents in various areas of physical chemistry and editor of “Polymorphism – In the Pharmaceutical Industry”, Wiley-VCH, 2006.

Rolf HilfikerSolvias

Wouter Driessen
As a project leader at Roche, Wouter is responsible for the early implementation of integrated, preclinical DMPK/PD strategies across various therapeutic modalities (small molecules, novel antibody constructs, oligonucleotides, and cell therapies), with a focus on (onco-)immunology and inflammation. Wouter received his Ph.D. in pharmaceutics at the University of Florida. He joined iThera Medical that is driving the field of optoacoustic imaging, both for preclinical and clinical use. In 2014, Wouter joined F. Hoffmann-La Roche as a DMPK/PD project leader.

Wouter DriessenPrincipal scientist, Roche, Shanghai

Guocai Lu
Guocai Lu currently serves as general manager of CTI Biotechnology with following part-time position or memberships: Expert of New Drug Evaluation, National Medical Products Administration; Expert of GLP Inspection, National Medical Products Administration; Deputy director, Division of Drug Toxicology, Chinese Pharmacological Society; Deputy director, Division of Safety Pharmacology, Chinese Pharmacological Society; Deputy director, Division of Drug Toxicology and Safety Evaluation, Chinese Society of Toxicology; Vice-president of Jiangsu Society of Toxicology. Dr. Lu has completed more than 300 new drug preclinical safety evaluations, of which more than 50 new drugs have been approved for clinical trials. He published over 130 articles and five monographs. Until now, Dr. Lu has applied for ten patents.

Guocai LuCTI Biotechnology

Dafang Zhong
Dr. Zhong obtained his Ph.D. (1989) degree in Pharmaceutical Chemistry from the University of Bonn, Germany. From 1994-2005, he worked as a professor in Shenyang Pharmaceutical University. Since June 2005, he has led the Center for DMPK Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has published more than 400 papers He is a member of Chinese Pharmacopeia Commission and drafted the Guidance for Bioavailability and Bioequivalence Studies for Drug Preparations as well as Guidelines for Bioanalytical Method Validation for Chinese Pharmacopeia 2015. He also severs as an editor for Biomedical Chromatography, Journal of Chromatography B, and Bioanalysis.

Dafang ZhongProfessor and PI


Emerging technologies in drug discovery and developments is annual conference taking place in alternate European/Eastern Asia regions
Learn more


One or two-day intensive courses designed for students and pharmaceutical researchers who wish to broaden their knowledge and advance in the career.
More details

Social events

Rich social events will provide relaxed atmosphere for getting togehter
More Details